USA News Group News Commentary ? As the new administration starts to make its mark in the United States, President Trump recently announced a $500 billion AI infrastructure investment in the country, ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity ...

Servier is extending its pact with Google Cloud as the French biopharma points to 60 examples of how generative artificial intelligence could improve its drug development processes. The two ...

The FDA has approved Eli Lilly’s Omvoh (mirikizumab-mrkz ... According to the company, Omvoh is the first biologic drug in over 15 years to provide the FDA with two-year Phase III efficacy data at ...

Generative AI will prove transformational for drug discovery in the healthcare industry. With the use of deep learning and advanced algorithms, generative AI can promote acceleration in the design and ...

These considerations will be valuable to sponsors (i.e., of clinical investigations, such as Investigational New Drug Exemption applications), along with AI model developers and other firms in the ...

Jan 15 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's disease, a type of chronic ...

Eli Lilly announced preliminary ... inventories (wholesaler stocking) for diabetes drug Mounjaro and obesity drug Zepbound. Why it matters: Lilly's growth prospects are driven by Mounjaro and ...

FILE PHOTO: An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. REUTERS/Brendan McDermid/File Photo · REUTERS / Reuters JPMorgan analyst ...

Eli Lilly expects about $3.5 billion in revenue for its diabetes treatment Mounjaro and $1.9 billion for its obesity drug Zepbound. CEO Dave Ricks told CNBC that the company has "tons of supply ...